Media Releases

Kingenic enters GI therapeutics market.

We identify gastrointestinal theapeutic as an important area of treatment. With our entry into GI segment, Kingenic is commited to make maximum impact in coming years.

Kingenic launches NSAID range in India

Kingenic announces the Indian launch of Kinamol, it is set to enter NSAID market.  NSAIDs represent a critically important class of medications, Kingenic is commited to launch several more product under this class.

Kingenic introduces QR packaging security

Counterfeiting products cause financial losses for legitimate brands, involve social costs and losses of unpaid tax for governments. Kingenic Lifescience has implemented quick response code system on our latest packaging material to enhance traceability.